Immuno-Oncology

FS118, an investigational LAG-3/PD-L1 bispecific antibody, demonstrated an encouraging objective response rate in the relapsed/refractory DLBCL setting.

Monica H. Vetter, MD, discusses the integration of immunotherapy into chemotherapy regimens for frontline advanced endometrial cancer.

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2024.

Nataliya Uboha, MD, PhD, and Robert Albert Anders, MD, PhD, unpack the unfavorable risk-benefit profile of PD-1 inhibitors in patients with certain PD-L1–negative gastrointestinal cancers and discussions from a recent ODAC meeting.

Zanidatamab scores approval for HER2+ biliary tract cancer, Versamune HPV is under exploration in HPV16+ head and neck squamous cell carcinoma, and more.

Experts discuss the ongoing investigation of Versamune HPV plus pembrolizumab and its potential effect on outcomes in first-line HPV16-driven HNSCC.

New datopotamab deruxtecan BLA in NSCLC filed to FDA, radiopharmaceutical meets rPFS end point in PSMA+ prostate cancer, and more.

Alex F. Herrera, MD, discusses long-term data from nivolumab plus AVD in advanced-stage Hodgkin lymphoma.

The investigational PRAME-targeted T-cell therapy IMA203 generated responses in melanoma and other solid tumors,

E-602 plus cemiplimab elicited preliminary antitumor activity and had a tolerable safety profile in PD-(L)1–resistant solid tumors.

David A. Braun, MD, PhD, discusses the potential for protein glycosylation as a biomarker to predict nivolumab/cabozantinib responses in advanced RCC.

The Immune Profile Score algorithmic test is now available for clinical use as a prognostic tool for immune checkpoint inhibitors in solid tumors.

DK210 (EGFR) showed evidence of wild-type IL-2 signaling, CRS mitigation, and immune response signaling in patients with solid tumors.

Here is your snapshot of all therapeutic options that the FDA approved in October 2024 spanning tumor types.

FDA accepts rivoceranib/camrelizumab NDA for review in HCC, acalabrutinib triplet yields responses in untreated mantle cell lymphoma, and more from OncLive this week.

Breelyn Wilky, MD, discusses updated efficacy and safety findings following treatment of botensilimab and balstilimab in refractory metastatic sarcoma.

Lurbinectedin plus atezolizumab produced significant OS and PFS benefits as frontline maintenance for extensive-stage small cell lung cancer.

The DetermaIO gene expression test was predictive of responses to neoadjuvant atezolizumab plus chemotherapy in early-stage triple-negative breast cancer.

Inavolisib triplet wins FDA approval in PIK3CA+ breast cancer, perioperative pembrolizumab improves EFS in head and neck cancer, and more from OncLive this week.

Jacqueline Brown, MD, explains the need to determine optimal second-line bladder cancer treatments for use after enfortumab vedotin/pembrolizumab.

Perioperative treatment with pembrolizumab and adjuvant radiotherapy improved EFS vs adjuvant radiotherapy in locally advanced head and neck squamous cell carcinoma.

Gotistobart plus pembrolizumab demonstrated antitumor activity and a manageable safety profile in platinum-resistant ovarian cancer.

Perioperative nivolumab receives FDA approval for resectable NSCLC, acalabrutinib sNDA gets priority review for MCL, and more from OncLive this week.

Here is your snapshot of all treatment options that the FDA approved in September 2024.

Maintenance with GRANITE plus fluoropyrimidine, bevacizumab, and checkpoint inhibitors improved PFS vs fluoropyrimidine plus bevacizumab alone in MSS mCRC.

The data are part of the largest reported cohorts of consecutive and uniformly treated real-world patients with newly diagnosed multiple myeloma.

A sBLA has been submitted to the FDA for subcutaneous daratumumab plus VRd in ASCT-ineligible or -deferred multiple myeloma.

The FDA’s ODAC votes against the risk:benefit profile of frontline PD-1 inhibitors in select tumor types, osimertinib gains approval for select NSCLC, and more this week from OncLive.

The FDA’s ODAC voted against the risk:benefit profile of anti–PD-1 therapy in first-line metastatic ESCC with a PD-L1 of less than 1.

The FDA’s ODAC voted against the risk:benefit profile of PD-1 inhibitors in first-line advanced gastric/GEJ adenocarcinoma with a PD-L1 of less than 1.